113 results about "Neutralizing antibody" patented technology

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody 1D3 for detecting porcine epidemic diarrhea virus (PEDV) and its applications. Its heavy chain variable region CDR sequences are SEQ ID NO. 1-3, and its light chain variable region CDR sequences are SEQ ID NO. 4-6. This antibody specifically recognizes the PEDV / S1 protein, and its binding can be competitively blocked by PEDV-specific neutralizing antibodies in serum, making it suitable for establishing a blocking ELISA method. Detection tools based on this antibody exhibit high specificity and sensitivity, with blocking rates exceeding 50% against PEDV-positive serum. This invention can be used to prepare detection kits or evaluate vaccine immunization efficacy, providing an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The high pathogenicity of the rift valley fever virus limits the research on the pathogenic mechanism and prevention, control and treatment products of the rift valley fever virus, the offspring replication-deficient virus particles are successfully saved through a reverse genetic manipulation technology, and the virus particles do not have the capacity of multiple rounds of infection on common cells; stable replication and passage can only be realized in a cell line for providing exogenous envelope glycoprotein; in addition, the virus particle carries an exogenous indication protein and can indicate cell infection. The Rift Valley fever virus-like particle provided by the invention can be used as a Rift Valley fever biosafety secondary laboratory research platform, the establishment of the virus particle greatly simplifies tedious procedures in the Rift Valley fever virus research process, and paves a way for screening of Rift Valley fever virus neutralizing antibodies, research and development of candidate vaccines and research of pathogenic mechanisms of the Rift Valley fever viruses.

The invention relates to a ZIKV nano vaccine as well as a construction method and application thereof, the ZIKV nano vaccine is prepared by mixing an SC-Mi3 fusion protein and an EDIII-ST fusion protein, and carrying out self-assembly connection through a SpyTag connecting peptide in the SC-Mi3 fusion protein and a SpyCatcher connecting peptide in the EDIII-ST fusion protein, so as to obtain a nano particle vaccine with Mi3 as a core and ZIKV EDIII protein displayed on the surface. The SC-Mi3 fusion protein is formed by fusing a SpyCatcher connecting peptide into Mi3 nano particles, and the EDIII-ST fusion protein is formed by fusing a SpyTag connecting peptide into a ZIKV EDIII protein. The ZIKV nano vaccine can induce a strong specific neutralizing antibody aiming at ZIKV, can resist lethal attack of ZIKV and avoids ADE reaction.

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

The invention relates to a method or regimen comprising the administration of IgG cysteine protease to a subject in order to improve the benefit of a subsequent vector-based therapy, where the vector-based therapy treats a disease or condition in said subject. Accordingly, the invention also relates to the treatment of diseases or conditions with a vector-based therapy. The method comprises administering to the subject at least two doses of an IgG cysteine protease; and subsequently administering said vector-based therapy. Methods of the invention are particularly useful for subjects who have pre-existing immunity or pre-existing neutralizing antibodies against the vector-based therapy.

This invention discloses a virulent strain of type II canine adenovirus, an inactivated vaccine, and their applications, belonging to the field of biotechnology. The virulent strain of type II canine adenovirus is named canine adenovirus type 2 Aa05 strain, with accession number CCTCC NO: V202605. The virus titer can reach 10. 6.0 TCID 50 / mL. This invention utilizes this strain to construct an animal model of canine adenovirus type II infection. This animal model exhibits typical clinical symptoms and can be used for future canine adenovirus vaccine development, immune protection assessment, and efficacy evaluation of preventive and therapeutic drugs. This invention also utilizes this strain to develop an inactivated vaccine with extremely high safety and immunogenicity. It can induce the body to produce high levels of specific neutralizing antibodies, which can protect immunized animals against infection with virulent CAV-2 strains and also against infection with highly pathogenic CAV-1 strains, demonstrating excellent cross-protection.

Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment.

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

The application discloses a novel trimeric recombinant protein vaccine. Specifically disclosed are a mutant protein RBD8M with an amino acid sequence of SEQ ID No. 1 and a fusion protein of positions 26-277, positions 1-277 and SEQ ID No. 4. The application also discloses a vaccine containing the fusion protein, and further develops a trimeric recombinant protein vaccine containing the fusion protein and a double adjuvant. Experiments show that the vaccine prepared in the application can effectively induce cellular immunity and humoral immunity of the body in animals, a trace amount of the protein can stimulate a very high immune response of mice, has a good protection effect, can simultaneously produce high-titer neutralizing antibodies against various epidemic strains of the novel coronavirus, is a broad-spectrum effective new coronavirus vaccine, and has important significance for preventing novel coronavirus infection and a wide clinical application prospect.

The invention provides a fusion protein vaccine and application thereof. Specifically, the invention provides a fusion protein and a pharmaceutical composition of the fusion protein and an STING agonist, and provides application of the pharmaceutical composition. According to the fusion protein vaccine disclosed by the invention, the titers of a specific neutralizing antibody and a binding antibody are remarkably improved, the broad spectrum and durability are enhanced, and the immune response of T cells is remarkably improved; besides, the fusion protein vaccine promotes the generation of memory T and B cells, effectively improves immune memory induced by the vaccine, provides a new strategy for preventing and / or treating diseases induced by respiratory tract infection, and has a wide application prospect.

This invention relates to the application of LAG3 agonists in the preparation of drugs for hematoma clearance after intracerebral hemorrhage (ICH) and the application of LAG3 in regulating hematoma clearance after ICH, belonging to the field of biomedical technology. This invention utilizes a mouse ICH model to first inject a LAG3 neutralizing antibody (C9B7W) via orthotopic injection, clarifying that LAG3 can regulate the phagocytic function of microglia after ICH and participate in hematoma clearance, revealing its potential molecular target for enhancing microglia phagocytic function and promoting hematoma clearance. Furthermore, overexpression of LAG3 after ICH is demonstrated. Lag3 The study confirmed that enhanced phagocytic function of microglia accelerated hematoma clearance, demonstrating that LAG3 agonists can be used as drugs for hematoma clearance after intracerebral hemorrhage. The experimental results of this invention make it possible to apply LAG3 to the prognostic treatment of ICH, thereby advancing basic and clinical research on endogenous hematoma clearance after ICH.

The application belongs to the technical field of biology and relates to a full human dual-specific antibody for a novel coronavirus (SARS-CoV-2) and use thereof. Specifically, the application relates to a dual-specific antibody for binding to a novel coronavirus (SARS-CoV-2), a preparation method thereof and use thereof, and further relates to a vector for expressing the dual-specific antibody, a host cell, a preparation and purification method. The dual-specific antibody has broad binding and neutralizing capabilities, and the dual-specific antibody can be used for preparing a medicine for treating or preventing a disease caused by a novel coronavirus infection, and for preparing a product for detecting or diagnosing a novel coronavirus.

This invention relates to a human monoclonal neutralizing antibody targeting the metapneumovirus F protein and its applications. It comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes complementary determinant regions HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively; and / or, the light chain variable region includes complementary determinant regions LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:4, AAS, and SEQ ID NO:5, respectively. The metapneumovirus monoclonal neutralizing antibody MV32 of this invention can specifically bind to the metapneumovirus F antigen (approximately 0.6 nM) and exhibits good broad-spectrum neutralizing activity against representative strains such as hMPV A1, hMPV B1, and hMPV A2b. It also possesses certain in vivo protective and preventative effects and can be used for the prevention and treatment of human metapneumovirus infection, showing great application potential.

The present invention relates to a novel system for the detection and quantification of neutralizing antibodies to either adeno-associated virus (AAV) or recombinant AAV vectors, with improved sensitivity and specificity.

The present disclosure relates to monoclonal human antibodies, or binding fragments thereof, directed against the CD4 binding site of human immunodeficiency virus HIV-1, pharmaceutical compositions comprising such monoclonal human antibodies, or binding fragments thereof, kits comprising such antibodies, or binding fragments thereof, and monoclonal antibodies or binding fragments thereof as well as pharmaceutical compositions and kits for use as medicaments and for the treatment or prevention of diseases caused by human immunodeficiency virus HIV-1.

This invention relates to the field of pharmaceutical technology, specifically to the novel use of avenanthramide A in the preparation of drugs for repairing liver damage. Experiments have demonstrated that the addition of avenanthramide A to activated macrophages significantly promotes the expression of tumor necrosis factor-α (TNF-α). Furthermore, co-culturing macrophages stimulated with avenanthramide A with hepatocytes effectively promotes hepatocyte proliferation. The addition of a TNF-α neutralizing antibody reverses this proliferative effect. This experiment confirms that avenanthramide A can promote hepatocyte proliferation and liver damage repair by increasing TNF-α expression in macrophages. This invention provides a novel drug target for enhancing hepatocyte proliferation.

The application discloses a kind of based on HIV envelope protein chimeric exosome and its preparation method and application, belong to biological medicine technical field.The application first constructs the cell line of stable expression HIV envelope protein Env, obtains engineered exosome from cell culture supernatant separation and purification;The exosome is used as immunogen combined with adjuvant immunization experimental animal, and high-efficiency induction specific humoral immune response;Again, obtain Env antigen specificity single B cell by flow cytometry sorting, obtain antibody variable region gene by single cell lysis, reverse transcription and nest PCR amplification, cloning to expression vector and expressing in mammalian cell, finally, HIV specific neutralizing antibody is screened by binding activity, affinity and neutralizing activity;The application is combined with single B cell antibody screening technology by embedding HIV Env antigen in the form of membrane combination in exosome surface, and realizes the synergistic optimization of antigen delivery and antibody screening process.

Provided are an antibody against human parainfluenza virus type 3, a bispecific antibody against human parainfluenza virus type 3 and respiratory syncytial virus, a nucleic acid molecule encoding the antibody and / or the bispecific antibody, a vector comprising the nucleic acid molecule, a host cell comprising the nucleic acid molecule or the vector, and a pharmaceutical composition comprising the antibody and / or the bispecific antibody. Also provided are a method for preparing and purifying the antibody and / or the bispecific antibody, and a use of the antibody and / or the bispecific antibody.

The invention belongs to the technical field of genetic engineering, and particularly relates to a bovine group A rotavirus multi-epitope fusion protein and application thereof. The invention provides a bovine group A rotavirus multi-epitope peptide based on a ferritin nano-carrier, a fusion protein and application of the bovine group A rotavirus multi-epitope peptide and the fusion protein. The multi-epitope peptide disclosed by the invention is a multi-epitope fusion antigen which is formed by splicing cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity and is formed by screening and obtaining the cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity on the basis of VP4 and VP7 protein sequences of bovine group A rotaviruses by utilizing an immunoinformatics technology. Immunological evaluation shows that the monoclonal antibody has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and the fusion protein can induce an organism to generate high-level neutralizing antibodies aiming at BRVA G6, G8, G10 and other multi-genotype strains, and the broad spectrum and durability of immune protection are remarkably improved.

To provide a modified mycoplasma protein M.SOLUTION: Provided is a modified Mycoplasma protein M or a functional fragment thereof, wherein the modified Mycoplasma protein M or a functional fragment thereof has one or more amino acid mutations that increase or maintain the thermostability of the Mycoplasma protein M or a functional fragment thereof as compared to a wild-type Mycoplasma protein M or a functional fragment thereof.SELECTED DRAWING: Figure 1

The present invention provides isolated Clostridium difficile binary toxin antibodies that are capable of neutralizing binary toxin with high potency, polypeptides and nucleic acids encoding the same, and methods of use thereof.

The application relates to the field of biological medicine, and provides a tetravalent antibody for neutralization of a novel coronavirus, which comprises an antibody monomer nAb and an scFv structure coupled at the Fc end of the heavy chain of the antibody monomer through a linker 1. Compared with the nAb antibody, the tetravalent antibody has higher antiviral capacity for various epidemic strains of the novel coronavirus, and has good application value.

The invention belongs to the technical field of medicine, and particularly relates to novel application of oat alkaloid A in preparation of medicine for repairing liver injury. Experiments prove that the expression of a tumor necrosis factor TNF-alpha can be remarkably promoted by adding the avenanthramide A into the activated macrophages, the proliferation of the hepatocytes can be effectively promoted after the macrophages stimulated by the avenanthramide A and the hepatocytes establish a co-culture system, and the proliferation effect of the hepatocytes is reversed after a TNF-alpha neutralizing antibody is added. The experiment proves that the oat alkaloid A can promote liver cell proliferation and liver injury repair by improving TNFa expression of macrophages. The invention can provide a new drug target for improving hepatocyte proliferation.

The present invention belongs to the fields of bioengineering and biological treatment. Disclosed are an anti-ADM monoclonal antibody or a fragment thereof and a pharmaceutical composition, a detection reagent, or a kit comprising the monoclonal antibody or the fragment thereof. Further disclosed is use of the monoclonal antibody or the fragment thereof in the preparation of a drug.

The present invention relates to a mouse SCF-neutralizing antibody and uses thereof. Specifically, the present invention relates to an antibody for neutralizing mouse SCF, comprising a heavy and a light chain of specific sequences, or an antigen-binding fragment thereof. A novel antibody is constructed for neutralizing SCF to inhibit SCF / c-kit signaling, leading to the development of a therapeutic agent for inhibiting abnormal angiogenesis, suppressing differentiation, proliferation, and degranulation of mast cells, and restraining proliferation of smooth muscle cells.

Provided are an oncolytic virus preparation capable of crossing a blood-brain barrier, a preparation method therefor and a use thereof. The oncolytic virus preparation is an oncolytic virus modified by a polypeptide having a function of crossing a blood-brain barrier. The polypeptide having the function of crossing the blood-brain barrier is RVG29-Cys. The oncolytic virus is a genetically engineered oncolytic virus OH2 in which neurotoxic and immunosuppressive genes in a wild-type virus genome are knocked out and an immune-enhancing human granulocyte-macrophage colony stimulating factor gene is inserted. An OH2-PEG-RVG nanosystem is constructed by conjugating NHS-PEG-Mal to OH2, and then coupling a Mal group on NHS-PEG-Mal to a Cys group on RVG29-Cys, thus increasing the aqueous solubility of a drug while facilitating the therapeutic drug crossing of the blood-brain barrier to treat brain tumors, and preventing neutralizing antibodies and macrophages in vivo from neutralizing and phagocytosing the oncolytic virus, thereby prolonging the circulation time in vivo.

The present disclosure provides an anti-tetanus toxin neutralizing antibody as a new generation of tetanus passive immunization preparation. The antibody can be fully human, which can specifically bind to full-length tetanus toxin and its AB fragment, has high affinity, high specificity, small toxic side effects, avoids the problems of large adverse reactions and short half-life of animal-derived monoclonal antibodies, and is prepared in large quantities by mammalian cells, and has clear and stable components.

The invention relates to the technical field of immunology and biology, and discloses a porcine epidemic diarrhea virus monoclonal neutralizing antibody which is named as PEDV-4C4F6. The antibody comprises a heavy chain and a light chain, and variable region amino acid sequences are respectively SEQ ID NO: 3 and SEQ ID NO: 4; wherein the heavy chain CDR is GYTFANYW, IFPGSGNT and TRTGAFAY in sequence, and the light chain CDR is ENVGTY, YGASK and GQSFTYPLT in sequence. The corresponding coding nucleic acids are respectively SEQ ID NO: 1 and SEQ ID NO: 2. The antibody can be obtained through immune recombination of PEDV S protein and hybridoma screening; the VH / VL can also be cloned to a eukaryotic expression vector for recombinant expression in 293S cells. An in-vitro neutralization test shows that the antibody has remarkable neutralization activity on a classical strain CV777, a vaccine strain AJ1102 and an epidemic strain ZL29, and the neutralization titer is greater than or equal to 1: 512; the subtype identification shows that the monoclonal antibody is IgG2a / kappa. The antibody is clear in sequence, high in specificity and easy to recombine and produce.

The invention relates to a herpes simplex virus type 2 (HSV-2) mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The mRNA vaccine encodes the variant of the HSV-2 UL37 protein, the protein structure of the variant is more stable, and a nucleotide sequence corresponding to the variant is optimized by a codon, so that the stability and the protein expression level of mRNA are improved. The mRNA further comprises a 5 '-untranslated region, a 3'-untranslated region and a Poly (A) tail, and is delivered through lipid nanoparticles (LNP). The mRNA vaccine disclosed by the invention can induce stronger specific neutralizing antibody and T cell immune response, and has a good application prospect in prevention or treatment of HSV-2 infection.